Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain

被引:216
作者
Kreuter, Jorg
Hekmatara, Telli
Dreis, Sebastian
Vogel, Tikva
Gelperina, Svetlana
Langer, Klaus
机构
[1] Univ Frankfurt, Inst Pharmazeut Technol, Biozentrum, D-60438 Frankfurt, Germany
[2] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA
[3] NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA
[4] Res Ctr Mol Diagnost & Therapy, Moscow, Russia
关键词
nanoparticles; apolipoprotein A-I; apolipoprotein B-100; apolipoprotein E3; human serum albumin (HSA); brain uptake; drug targeting;
D O I
10.1016/j.jconrel.2006.12.012
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Apolipoprotein E3, A-I as well as B-100 were covalently attached to human serum albumin nanoparticles via the NES-PEG-Mal 3400 linker. Loperamide as a model drug was bound to these nanoparticles, and the antinociceptive reaction of these preparations was recorded after intravenous injection in mice by the tail-flick test. After 15 min, all three nanoparticle preparations with the coupled apolipoproteins E3, A-I, and B-100 yielded considerable antinociceptive effects, which lasted over 1 h. The maximally possible effects [MPE] of these preparations amounted to 95%, 65%, and 50%, respectively, and were statistically different from the controls (p < 0.02), whereas the loperamide solution achieved no effect. This result demonstrates that more than one mechanism is involved in the interaction of nanoparticles with the brain endothelial cells and the resulting delivery of drugs to the central nervous system. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:54 / 58
页数:5
相关论文
共 28 条
[1]   Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles [J].
Alyautdin, RN ;
Petrov, VE ;
Langer, K ;
Berthold, A ;
Kharkevich, DA ;
Kreuter, J .
PHARMACEUTICAL RESEARCH, 1997, 14 (03) :325-328
[2]   Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study [J].
Alyautdin, RN ;
Tezikov, EB ;
Ramge, P ;
Kharkevich, DA ;
Begley, DJ ;
Kreuter, J .
JOURNAL OF MICROENCAPSULATION, 1998, 15 (01) :67-74
[3]   Uptake and transport of high-density lipoprotein (HDL) and HDL-associated α-tocopherol by an in vitro blood-brain barrier model [J].
Balazs, Z ;
Panzenboeck, U ;
Hammer, A ;
Sovic, A ;
Quehenberger, O ;
Malle, E ;
Sattler, W .
JOURNAL OF NEUROCHEMISTRY, 2004, 89 (04) :939-950
[4]   Determination of loperamide in rat plasma and bovine serum albumin by LC [J].
Chen, H ;
Gaul, F ;
Guo, D ;
Maycock, A .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 22 (03) :555-561
[5]   Two apolipoprotein E mimetic peptides, ApoE(130-149) and ApoE(141-155)2, bind to LRP1 [J].
Croy, JE ;
Brandon, T ;
Komives, EA .
BIOCHEMISTRY, 2004, 43 (23) :7328-7335
[6]   A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier [J].
Dehouck, B ;
Fenart, L ;
Dehouck, MP ;
Pierce, A ;
Torpier, G ;
Cecchelli, R .
JOURNAL OF CELL BIOLOGY, 1997, 138 (04) :877-889
[7]  
DELOOF H, 1986, P NATL ACAD SCI USA, V83, P2295
[8]   Apolipoprotein E structure and substrate and receptor-binding activities of triglyceride-rich human plasma lipoproteins in normo- and hypertriglyceridemia [J].
Dergunov, AD .
BIOCHEMISTRY-MOSCOW, 2004, 69 (07) :720-737
[9]   Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system [J].
Friese, A ;
Seiller, E ;
Quack, G ;
Lorenz, B ;
Kreuter, J .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 49 (02) :103-109
[10]   The role of plasma proteins in brain targeting:: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles [J].
Gessner, A ;
Olbrich, C ;
Schröder, W ;
Kayser, O ;
Müller, RH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 214 (1-2) :87-91